RSAD2 and neoplasm: Although the initial CCM screen evaluated associations with a gene signature of immune activity, including TLS formation, the emerging CCMs covered genes that are expressed by tumor cells (e.g., RSAD2, CMPK2) and stromal fibroblasts (e.g., SUCNR1) as well as immune cells (e.g., POU2F2).